Fig. 19
From: The progression of inorganic nanoparticles and natural products for inflammatory bowel disease
Schematic diagram of UC treatment in mice with CP/HA/RH-NPs. (1) Schematic diagram of oral CP/HA/RH-NPs via the GIT. CP can protect CP/HA/RH-NPs through the stomach and small intestine and further release HA/RH-NPs into the colonic lumen through degradation. (2) Schematic diagram of enhancing the effect of RH in repairing intestinal damage by targeting the expression of ZO-1 and Claudin-1 in UC mouse models through colonic epithelial cells. (3) The schematic of targeting macrophages can effectively promote the anti-inflammatory effect of RH through the TLR4/MyD88/NF-κB pathway and the anti-UC therapeutic effect in vivo. (Quoted in Luo et al. [160])